NeurologyLive® Friday 5 — October 6, 2023

Welcome to NeurologyLive^®'s Friday 5! Every week, the staff compiles 5 highlights of NeurologyLive^®'s widespread coverage in neurology, ranging from newsworthy study findings and FDA action to expert interviews and peer-to-peer panel discussions.

1: The Effects of Depression in Parkinson Disease and Need for Mental Health Professionals: James Beck, PhD

The senior vice president and chief scientific officer of the Parkinson’s Foundation provided perspective on the reasons for the lack of mental health specialists in Parkinson disease care and the complexities behind treating depression. [WATCH TIME: 4 minutes]

2: Real-World Experience With Ofatumumab

Jason Freeman, MD, MBA, and James Stankiewicz, MD, discuss the poster “Real-World Experience With Ofatumumab” presented at ACTRIMS 2023. Sponsored By Novartis.

3: NeuroVoices: Sarah Todd Hammer on Changing the Perceptions and Conversations on Neurologic Disability

After being diagnosed with acute flaccid myelitis more than 10 years ago, patient advocate Sarah Todd Hammer spoke on the ways in which disability should be viewed and discussed.

4: Emerging Trends That Challenge the Landscape of Care for Multiple Sclerosis: Stephen Krieger, MD

The associate professor of neurology at Icahn School of Medicine at Mount Sinai talked about the promising new treatments for multiple sclerosis, the significance of the spinal cord in the disease, and the use of artificial intelligence in neuroimaging. [WATCH TIME: 3 minutes]

5: Treatment Decision Process for Subarachnoid Hemorrhage: Guilherme Dabus, MD

The codirector of interventional neuroradiology and vice-chief of the department of neuroscience at Baptist Health Miami Neuroscience Institute provided clarity on the complexities with treating subarachnoid hemorrhage on an individual case basis. [WATCH TIME: 4 minutes]